EU reviewed the gaps for Maximum Residue levels of 2,4-D, azoxystrobin, cyhalofop-butyl, cymoxanil, fenhexamid, flazasulfuron, florasulam, fluroxypyr, iprovalicarb and silthiofam. For example, in case of azoxystrobin it proposed lowering the MRLs for some products and for cyhalofop-butyl, cymoxanil and fenhexamid the requirement to submit additional information should be deleted.